NASDAQ: ELTX - Elicio Therapeutics, Inc.

Rentabilidade por seis meses: +51.92%
Rendimento de dividendos: 0.00%
Setor: Healthcare

Cronograma de promoção Elicio Therapeutics, Inc.

Agenda avançada Gráfico simples
Financial Markets by TradingView

Sobre a empresa Elicio Therapeutics, Inc.

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers.

mais detalhes
It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002; ELI-007, a lymph node targeted AMP-peptide vaccine for mutant BRAF-driven cancers; ELI-008, a multivalent lymph node targeted AMP-peptide vaccine for mutant TP53-expressing cancers; ELI-005, a vaccine candidate for the prevention of COVID-19; ELI-011 for the treatment of hematological cancers; and ELI-012, a mKRAS TCR T cell AMP-lifier designs to use in combination with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company is headquartered in Boston, Massachusetts.
Adicionar à lista de comparação
Adicionar à lista de observação
Adicionar ao portfólio
Adicionar aviso de preço

IPO date 2021-02-05
ISIN US28657F1030
Industry Pharmaceuticals
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://elicio.com
Цена ао 7.1
Alteração de preço por dia: +1.58% (5.07)
Alteração de preço por semana: +5.53% (4.88)
Alteração de preço por mês: +1.98% (5.05)
Alteração de preço em 3 meses: +1.78% (5.06)
Mudança de preço em seis meses: +51.92% (3.39)
Mudança de preço por ano: -38.25% (8.34)
Mudança de preço em 3 anos: +96.56% (2.62)
Mudança de preço em 5 anos: 0% (5.15)
Mudança de preço em 10 anos: 0% (5.15)
Mudança de preço desde o início do ano: -0.8662% (5.195)
Todos os parâmetros

Subestimação

Nome Significado Nota
P/S 0 0
P/BV 3.16 5
P/E 0 0
EV/EBITDA -0.8654 0
Total: 3.13

Eficiência

Nome Significado Nota
ROA, % -129.65 0
ROE, % -309.46 0
Total: 0

Dividendos

Nome Significado Nota
Div yield, % 0 0
DSI 0 0
Total: 0

Obrigação

Nome Significado Nota
Debt/EBITDA -0.2001 10
Total: 10

Impulso de crescimento

Nome Significado Nota
Rentabilidade Revenue, % 875.86 10
Rentabilidade Ebitda, % 170.21 10
Rentabilidade EPS, % 364.05 10
Total: 10
Mais detalhes

Instituições Volume Compartilhar, %
Vanguard Group Inc 174894 1.71
CM Management, LLC 50000 0.49
Geode Capital Management, LLC 44344 0.43
Renaissance Technologies, LLC 16466 0.16
Citadel Advisors Llc 14005 0.14
Meyer Handelman Co 13899 0.14
Bridgeway Capital Management, Inc. 12500 0.12
Tower Research Capital LLC (TRC) 2045 0.02
Steward Partners Investment Advisory, LLC 1554 0.02
Bank of America Corporation 1149 0.01

ETF Compartilhar, % Rentabilidade para o ano, % Dividendos, %
iShares Micro-Cap ETF 0.00961 17.09 1.54048



Supervisor Cargo Pagamento Ano de nascimento
Mr. Robert T. Connelly CEO, President & Director 612k 1960 (65 anos)
Dr. Christopher M. Haqq M.D., Ph.D. Executive VP, Head of Research & Development and Chief Medical Officer 589k 1966 (59 anos)
Prof. Darrell J. Irvine Ph.D. Co-Founder, Consultant, Board Observer & Chairman of Scientific Advisory Board N/A
Mr. Michael DiVecchia Senior Vice President of Operations & Human Resources N/A
Dr. Peter DeMuth Ph.D. Chief Scientific Officer N/A 1986 (39 anos)
Ms. Esther Welkowsky Senior Vice President of Clinical Development N/A
Ms. Joy Seymour VP & Head of Regulatory Affairs N/A
Ms. Megan C. Filoon General Counsel, Secretary & Compliance Officer N/A
Dr. Thian Kheoh Ph.D. Senior Vice President of Biometrics N/A

Endereço: United States, Boston. MA, 451 D Street - abrir no Google Maps, abrir mapas Yandex
Site: https://elicio.com